Amgen: A Biotech Pioneer On Sale


Recent negative sentiment mostly driven by political bashing of price gouging pharmaceutical companies have driven the prices down for pharma and biotech companies in general. Amgen relies heavily on a small number of patent protected products which give pause to investors who are concerned about patent expirations and product obsolescence.



from Biotech News